Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring

Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- an...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Microbiology spectrum Ročník 10; číslo 2; s. e0039622
Hlavní autori: Moeller, Maria E., Engsig, Frederik N., Bade, Melanie, Fock, Jeppe, Pah, Pearlyn, Soerensen, Anna Louise, Bang, Didi, Donolato, Marco, Benfield, Thomas
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Society for Microbiology 27.04.2022
Predmet:
Antibodies, Viral
COVID-19 - diagnosis
COVID-19 Vaccines
Humans
Immunoassay - methods
Immunoglobulin G
immunomagnetic agglutination assay
Pandemics
point-of-care
Point-of-Care Testing
rapid IgG-IgM-IgA combined test
Research Article
S protein trimer
SARS-CoV-2
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus
Vaccination
Vaccines
SARS-CoV-2
rapid IgG-IgM-IgA combined test
point-of-care
S protein trimer
immunomagnetic agglutination assay
vaccination
ISSN:2165-0497, 2165-0497
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank’s correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
AbstractList Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank's correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank's correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank’s correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank's correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank’s correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
ABSTRACT Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 spike trimeric spike protein compared to standard laboratory chemiluminescence (CLIA)-based tests. Antibody responses of 101 individuals were measured on capillary blood, venous whole blood, plasma, and diluted plasma samples directly on the POC. Results were available within 7 min. As the reference, plasma samples were analyzed on DiaSorin LIAISON XL CLIA analyzer using LIAISON SARS-CoV-2 IgM, LIAISON SARS-CoV-2 S1/S2 IgG, and LIAISON SARS-CoV-2 TrimericS IgG assays. The Spearman rank’s correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON SARS-CoV-2 S1/S2 IgG and LIAISON SARS-CoV-2 TrimericS IgG assays was found to be 0.83 and 0.89, respectively. ViroTrack Sero COVID-19 Total Ab showed high correlation between the different matrixes. Agreement for determination of samples of >230 binding antibody units (BAU)/mL on POC and CLIA methods is estimated to be around 90%. ViroTrack Sero Covid Total Ab is a rapid and simple-to-use POC test with high sensitivity and correlation of numerical results expressed in BAU/mL compared to those of a commercial CLIA assay. IMPORTANCE Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral flow assays, which perform only qualitatively and can be difficult for the individual to read, or standard laboratory assays, which are time- and resource-consuming. The purpose of the study was to evaluate the performance of a new POC microfluidic cartridge-based device based on immunomagnetic agglutination assay that can provide an accurate numerical quantification of the total antibodies within only 7 min from a single drop of capillary blood. We demonstrated a high level of correlation between the POC and the two CLIA laboratory-based immunoassays from Diasorin, thus allowing a potentially wider use of quantitative serology tests in the COVID-19 pandemic.
Author Fock, Jeppe
Bade, Melanie
Pah, Pearlyn
Engsig, Frederik N.
Donolato, Marco
Moeller, Maria E.
Benfield, Thomas
Soerensen, Anna Louise
Bang, Didi
Author_xml – sequence: 1
  givenname: Maria E.
  surname: Moeller
  fullname: Moeller, Maria E.
  organization: Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
– sequence: 2
  givenname: Frederik N.
  surname: Engsig
  fullname: Engsig, Frederik N.
  organization: Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
– sequence: 3
  givenname: Melanie
  surname: Bade
  fullname: Bade, Melanie
  organization: BluSense Diagnostics ApS, Copenhagen, Denmark
– sequence: 4
  givenname: Jeppe
  surname: Fock
  fullname: Fock, Jeppe
  organization: BluSense Diagnostics ApS, Copenhagen, Denmark
– sequence: 5
  givenname: Pearlyn
  surname: Pah
  fullname: Pah, Pearlyn
  organization: BluSense Diagnostics ApS, Copenhagen, Denmark
– sequence: 6
  givenname: Anna Louise
  surname: Soerensen
  fullname: Soerensen, Anna Louise
  organization: Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
– sequence: 7
  givenname: Didi
  surname: Bang
  fullname: Bang, Didi
  organization: Department of Clinical Microbiology, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
– sequence: 8
  givenname: Marco
  surname: Donolato
  fullname: Donolato, Marco
  organization: BluSense Diagnostics ApS, Copenhagen, Denmark
– sequence: 9
  givenname: Thomas
  surname: Benfield
  fullname: Benfield, Thomas
  organization: Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark, Institute of Clinical Medicine, Faculty of Health and Human Sciences, University of Copenhagen, Copenhagen, Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35357223$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1uEzEUhS1URNvQB2CDZslmgn9n7A1SlZYSqSiASreWx2MHRzN2sD2V-vY4SVu1LLrylX3up3Pv8Sk48sEbAD4gOEcI889pa3SO0ziHkIimxvgNOMGoYTWkoj16Vh-Ds5Q2EEKEIMMMvwPHhBHWYkxOQPdLbV1f_ZyUzy6r7O5M9SM4n-uVrRcqmurCqbUPKTtd3ZiUKxtiUZRisbpdXtRIVLdKa-dLb_DVecF0ob-vvgfvcojOr9-Dt1YNyZw9nDPw--vlzeJbfb26Wi7Or2vFIM21tb3WjCtNuoa0RBe_uBOUmLahvegR4hjCIoENb1tBlWgQQ5YTYWBrKbVkBpYHbh_URm6jG1W8l0E5ub8IcS1VLGMMRlKMjTCsIYRDyo3gSCHdw07x1hbgjvXlwNpO3Wh6bXyOangBffni3R-5DndSQMowYgXw6QEQw9-p7E2OLmkzDMqbMCWJG8o4Ewg1RTo_SFUasdyEKfqyJomg3OUsH3OW-5xlSW0GPj439-TqMdUiQAeBjiGlaOyT5DVo-1-P3v-HsJvPDa90_gOlrsqE
CitedBy_id crossref_primary_10_1128_spectrum_00809_24
crossref_primary_10_3390_v16101604
crossref_primary_10_1016_j_talanta_2022_123562
crossref_primary_10_1016_j_saa_2024_125337
crossref_primary_10_3390_chemosensors10060221
crossref_primary_10_1016_j_trac_2023_117361
crossref_primary_10_1063_5_0196224
crossref_primary_10_3390_biomedicines10112897
crossref_primary_10_1016_j_ejim_2022_11_009
crossref_primary_10_3390_bios15030195
Cites_doi 10.1101/2021.06.21.21258528
10.3390/diagnostics11040593
10.1093/clinchem/hvaa262
10.1016/bs.aivir.2019.08.002
10.1056/NEJMoa2109072
10.1101/2021.08.19.21262111
10.1093/clinchem/hvaa336
10.1515/cclm-2021-0023
10.1016/S1473-3099(20)30634-4
10.1016/S0140-6736(21)01642-1
10.1016/S0140-6736(21)00502-X
10.1128/JCM.01224-20
10.1093/clinchem/hvaa211
10.1002/jmv.26854
10.1056/NEJMe2028079
10.1021/acsnano.5b02379
10.1038/s41586-020-2852-1
10.1038/s41591-021-01377-8
10.1039/c6cp08749c
10.1101/2020.07.17.20140533
10.1016/S0262-4079(21)00808-3
10.1128/JVI.01828-20
10.12659/MSM.924700
10.1101/2020.09.23.20199604
10.1016/j.vaccine.2020.11.054
10.21873/invivo.12138
10.1128/Spectrum.00247-21
10.1101/2021.02.24.21252368
10.1016/S0140-6736(20)31604-4
10.1016/j.cell.2020.02.058
10.1126/science.abd7728
10.1056/NEJMoa2022483
10.1093/ofid/ofab043
10.1038/srep16145
10.1016/j.ebiom.2020.103101
10.1016/S0140-6736(21)00527-4
10.1128/JCM.02257-20
10.1056/NEJMoa2028436
10.1126/science.abc1227
10.1101/2021.04.27.21256205
10.1136/annrheumdis-2021-220656
ContentType Journal Article
Copyright Copyright © 2022 Moeller et al.
Copyright © 2022 Moeller et al. 2022 Moeller et al.
Copyright_xml – notice: Copyright © 2022 Moeller et al.
– notice: Copyright © 2022 Moeller et al. 2022 Moeller et al.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1128/spectrum.00396-22
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2165-0497
Editor Jhaveri, Tulip A
Editor_xml – sequence: 1
  givenname: Tulip A
  surname: Jhaveri
  fullname: Jhaveri, Tulip A
ExternalDocumentID oai_doaj_org_article_422e9e56338048e981a1cd0ba87f39ef
PMC9045215
00396-22
35357223
10_1128_spectrum_00396_22
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 53G
AAGFI
AAUOK
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
CITATION
EJD
FF~
FRP
GROUPED_DOAJ
H13
M~E
OK1
RPM
RSF
AGVNZ
CGR
CUY
CVF
ECM
EIF
NPM
BXI
EBS
FF
UCJ
7X8
5PM
ID FETCH-LOGICAL-a504t-ffdcc58ac3b6373c0012b943e764d9d118200dcc0687794a96151f839e07f44f3
IEDL.DBID DOA
ISICitedReferencesCount 10
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000835142100047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2165-0497
IngestDate Fri Oct 03 12:45:15 EDT 2025
Tue Sep 30 16:46:19 EDT 2025
Thu Oct 02 10:05:56 EDT 2025
Thu Apr 28 03:17:34 EDT 2022
Mon Jul 21 06:03:47 EDT 2025
Sat Nov 29 01:47:28 EST 2025
Tue Nov 18 20:45:57 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords SARS-CoV-2
rapid IgG-IgM-IgA combined test
point-of-care
S protein trimer
immunomagnetic agglutination assay
vaccination
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a504t-ffdcc58ac3b6373c0012b943e764d9d118200dcc0687794a96151f839e07f44f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare a conflict of interest. P. Pah, M. Bade, J. Fock, and M. Donolato are employed at Blusense Diagnostics APS and have been part of the developing of ViroTrack Sero COVID-19 Total Ab. This work was supported by BluSense Diagnostics who provided the test kits for the study.
OpenAccessLink https://doaj.org/article/422e9e56338048e981a1cd0ba87f39ef
PMID 35357223
PQID 2645859116
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_422e9e56338048e981a1cd0ba87f39ef
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9045215
proquest_miscellaneous_2645859116
asm2_journals_10_1128_spectrum_00396_22
pubmed_primary_35357223
crossref_primary_10_1128_spectrum_00396_22
crossref_citationtrail_10_1128_spectrum_00396_22
PublicationCentury 2000
PublicationDate 2022-04-27
PublicationDateYYYYMMDD 2022-04-27
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-27
  day: 27
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Microbiology spectrum
PublicationTitleAbbrev Microbiol Spectr
PublicationTitleAlternate Microbiol Spectr
PublicationYear 2022
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_27_2
Yanny B (e_1_3_2_25_2) 2019; 15
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
Padoan, A, Bonfante, F, Pagliari, M, Bortolami, A, Negrini, D, Zuin, S, Bozzato, D, Cosma, C, Sciacovelli, L, Plebani, M (B18) 2020; 62
Anderson, EJ, Rouphael, NG, Widge, AT, Jackson, LA, Roberts, PC, Makhene, M, Chappell, JD, Denison, MR, Stevens, LJ, Pruijssers, AJ, McDermott, AB, Flach, B, Lin, BC, Doria-Rose, NA, O'Dell, S, Schmidt, SD, Corbett, KS, Swanson, PA, Padilla, M, Neuzil, KM, Bennett, H, Leav, B, Makowski, M, Albert, J, Cross, K, Edara, VV, Floyd, K, Suthar, MS, Martinez, DR, Baric, R, Buchanan, W, Luke, CJ, Phadke, VK, Rostad, CA, Ledgerwood, JE, Graham, BS, Beigel, JH (B12) 2020; 383
Yanny, B, Konyn, P, Najarian, LM, Mitry, A, Saab, S (B24) 2019; 15
Šimánek, V, Pecen, L, Krátká, Z, Fürst, T, Řezáčková, H, Topolčan, O, Fajfrlík, K, Sedláček, D, Šín, R, Pazdiora, P, Zelená, H, Slouka, D, Kučera, R (B26) 2021; 11
Sadoff, J, leGars, M, Shukarev, G, Heerwegh, D, Truyers, C, de Groot, AM, Stoop, J, Tete, S, van Damme, W, Leroux-Roels, I, Berghmans, P-J, Kimmel, M, van Damme, P, de Hoon, J, Smith, W, Stephenson, KE, Barouch, DH, de Rosa, SC, Cohen, KW, McElrath, J, Cormier, E, Scheper, G, Hendriks, J, Struyf, F, Douoguih, M, van Hoof, J, Schuitemaker, H (B14) 2020
Krammer, F, Simon, V (B1) 2020; 368
Lawton, G (B33) 2021; 250
Jackson, LA, Anderson, EJ, Rouphael, NG, Roberts, PC, Makhene, M, Coler, RN, McCullough, MP, Chappell, JD, Denison, MR, Stevens, LJ, Pruijssers, AJ, McDermott, A, Flach, B, Doria-Rose, NA, Corbett, KS, Morabito, KM, O'Dell, S, Schmidt, SD, Swanson, PA, Padilla, M, Mascola, JR, Neuzil, KM, Bennett, H, Sun, W, Peters, E, Makowski, M, Albert, J, Cross, K, Buchanan, W, Pikaart-Tautges, R, Ledgerwood, JE, Graham, BS, Beigel, JH (B11) 2020; 383
Ainsworth, M, Andersson, M, Auckland, K, Baillie, JK, Barnes, E, Beer, S, Beveridge, A, Bibi, S, Blackwell, L, Borak, M, Bown, A, Brooks, T, Burgess-Brown, NA, Camara, S, Catton, M, Chau, KK, Christott, T, Clutterbuck, E, Coker, J, Cornall, RJ, Cox, S, Crawford-Jones, D, Crook, DW, D'Arcangelo, S, Dejnirattsai, W, Dequaire, JMM, Dimitriadis, S, Dingle, KE, Doherty, G, Dold, C, Dong, T, Dunachie, SJ, Ebner, D, Emmenegger, M, Espinosa, A, Eyre, DW, Fairhead, R, Fassih, S, Feehily, C, Felle, S, Fernandez-Cid, A, Fernandez Mendoza, M, Foord, TH, Fordwoh, T, Fox McKee, D, Frater, J, Gallardo Sanchez, V, Gent, N, Georgiou, D, Groves, CJ (B42) 2020; 20
Shields, AM, Faustini, SE, Kristunas, CA, Cook, AM, Backhouse, C, Dunbar, L, Ebanks, D, Emmanuel, B, Crouch, E, Kroeger, A, Hirschfeld, J, Sharma, P, Jaffery, R, Nowak, S, Gee, S, Drayson, MT, Richter, AG, Dietrich, T, Chapple, IC (B10) 2021
Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S, Bellamy, D, Bibi, S, Bittaye, M, Clutterbuck, EA, Dold, C, Faust, SN, Finn, A, Flaxman, AL, Hallis, B, Heath, P, Jenkin, D, Lazarus, R, Makinson, R, Minassian, AM, Pollock, KM, Ramasamy, M, Robinson, H, Snape, M, Tarrant, R, Voysey, M, Green, C, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ, Aboagye, J, Adams, K, Ali, A, Allen, E, Allison, JL, Anslow, R, Arbe-Barnes, EH, Babbage, G, Baillie, K, Baker, M, Baker, N, Baker, P, Baleanu, I, Ballaminut, J, Barnes, E, Barrett, J, Bates, L, Batten, A (B13) 2020; 396
Suhandynata, RT, Hoffman, MA, Huang, D, Tran, JT, Kelner, MJ, Reed, SL, McLawhon, RW, Voss, JE, Nemazee, D, Fitzgerald, RL (B20) 2021; 67
Antunes, P, Watterson, D, Parmvi, M, Burger, R, Boisen, A, Young, P, Cooper, MA, Hansen, MF, Ranzoni, A, Donolato, M (B40) 2015; 5
Bal, A, Pozzetto, B, Trabaud, M-A, Escuret, V, Rabilloud, M, Langlois-Jacques, C, Paul, A, Guibert, N, D'Aubarède-Frieh, C, Massardier-Pilonchery, A, Fabien, N, Goncalves, D, Boibieux, A, Morfin-Sherpa, F, Pitiot, V, Gueyffier, F, Lina, B, Fassier, J-B, Trouillet-Assant, S (B16) 2021; 67
Fock, J, Jonasson, C, Johansson, C, Hansen, MF (B41) 2017; 19
Bonelli, F, Blocki, FA, Bunnell, T, Chu, E, de La O, A, Grenache, DG, Marzucchi, G, Montomoli, E, Okoye, L, Pallavicini, L, Streva, VA, Torelli, A, Wagner, A, Zanin, D, Zierold, C, Wassenberg, JJ (B22) 2021; 59
Feng, S, Phillips, D, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M, Team, OVT (B29) 2021
Bonelli, F, Sarasini, A, Zierold, C, Calleri, M, Bonetti, A, Vismara, C, Blocki, FA, Pallavicini, L, Chinali, A, Campisi, D, Percivalle, E, DiNapoli, AP, Perno, CF, Baldanti, F (B17) 2020; 58
Wang, F, Kream, RM, Stefano, GB (B7) 2020; 26
Barnes, CO, Jette, CA, Abernathy, ME, Dam, K-MA, Esswein, SR, Gristick, HB, Malyutin, AG, Sharaf, NG, Huey-Tubman, KE, Lee, YE, Robbiani, DF, Nussenzweig, MC, West, APJ, Bjorkman, PJ (B5) 2020; 588
Wajnberg, A, Amanat, F, Firpo, A, Altman, DR, Bailey, MJ, Mansour, M, McMahon, M, Meade, P, Mendu, DR, Muellers, K, Stadlbauer, D, Stone, K, Strohmeier, S, Simon, V, Aberg, J, Reich, DL, Krammer, F, Cordon-Cardo, C (B9) 2020; 370
Sahin, U, Muik, A, Derhovanessian, E, Vogler, I, Kranz, LM, Vormehr, M, Baum, A, Pascal, K, Quandt, J, Maurus, D, Brachtendorf, S, Lörks, V, Sikorski, J, Hilker, R, Becker, D, Eller, A-K, Grützner, J, Boesler, C, Rosenbaum, C, Kühnle, M-C, Luxemburger, U, Kemmer-Brück, A, Langer, D, Bexon, M, Bolte, S, Karikó, K, Palanche, T, Fischer, B, Schultz, A, Shi, P-Y, Fontes-Garfias, C, Perez, JL, Swanson, KA, Loschko, J, Scully, IL, Cutler, M, Kalina, W, Kyratsous, CA, Cooper, D, Dormitzer, PR, Jansen, KU, Türeci, Ö (B15) 2020
Tang, MS, Case, JB, Franks, CE, Chen, RE, Anderson, NW, Henderson, JP, Diamond, MS, Gronowski, AM, Farnsworth, CW (B21) 2020; 66
Mahmoud, SA, Ganesan, S, Naik, S, Bissar, S, Zamil, I, Zaher, WA (B27) 2021
Kristiansen, PA, Page, M, Bernasconi, V, Mattiuzzo, G, Dull, P, Makar, K, Plotkin, S, Knezevic, I (B28) 2021; 397
Shrotri, M, Navaratnam, AMD, Nguyen, V, Byrne, T, Geismar, C, Fragaszy, E, Beale, S, Fong, WLE, Patel, P, Kovar, J, Hayward, AC, Aldridge, RW (B37) 2021; 398
Ura, T, Yamashita, A, Mizuki, N, Okuda, K, Shimada, M (B6) 2021; 39
Tortorici, MA, Veesler, D (B8) 2019; 105
Fenwick, C, Croxatto, A, Coste, AT, Pojer, F, André, C, Pellaton, C, Farina, A, Campos, J, Hacker, D, Lau, K, Bosch, B-J, Gonseth Nussle, S, Bochud, M, D’Acremont, V, Trono, D, Greub, G, Pantaleo, G (B23) 2021; 95
Alter, G, Seder, R (B2) 2020; 383
Morshed, M, Sekirov, I, McLennan, M, Levett, PN, Chahil, N, Mak, A, Carruthers, E, Pidduck, T, Kustra, J, Laley, J, Lee, MK, Chu, K, Burgess, F, Vijh, R, Willis, L, Wada, R, Blancaflor, R, Boraston, S, Hayden, A, Krajden, M (B35) 2021; 8
Perkmann, T, Perkmann-Nagele, N, Koller, T, Mucher, P, Radakovics, A, Marculescu, R, Wolzt, M, Wagner, OF, Binder, CJ, Haslacher, H (B25) 2021; 9
Patel, EU, Bloch, EM, Clarke, W, Hsieh, Y-H, Boon, D, Eby, Y, Fernandez, RE, Baker, OR, Keruly, M, Kirby, CS, Klock, E, Littlefield, K, Miller, J, Schmidt, HA, Sullivan, P, Piwowar-Manning, E, Shrestha, R, Redd, AD, Rothman, RE, Sullivan, D, Shoham, S, Casadevall, A, Quinn, TC, Pekosz, A, Tobian, AAR, Laeyendecker, O (B19) 2021; 59
Khoury, DS, Cromer, D, Reynaldi, A, Schlub, TE, Wheatley, AK, Juno, JA, Subbarao, K, Kent, SJ, Triccas, JA, Davenport, MP (B30) 2021; 27
Moeller, ME, Fock, J, Pah, P, Veras, ADLC, Bade, M, Donolato, M, Israelsen, SB, Eugen-Olsen, J, Benfield, T, Engsig, FN (B38) 2021; 93
Mezger, A, Fock, J, Antunes, P, Østerberg, FW, Boisen, A, Nilsson, M, Hansen, MF, Ahlford, A, Donolato, M (B39) 2015; 9
Walls, AC, Park, Y-J, Tortorici, MA, Wall, A, McGuire, AT, Veesler, D (B4) 2020; 181
Israel, A, Shenhar, Y, Green, I, Merzon, E, Golan-Cohen, A, Schäffer, AA, Ruppin, E, Vinker, S, Magen, E (B36) 2021
Fragkou, PC, Papaevangelou, V, Antoniadou, A, Kavvatha, D, Ploussi, A, Pantazis, N, Sirmpilantze, T, Psarrakis, C, Pournaras, SA, Tsiodras, S, Kelekis, A (B34) 2020; 34
Prendecki, M, Clarke, C, Brown, J, Cox, A, Gleeson, S, Guckian, M, Randell, P, Pria, AD, Lightstone, L, Xu, X-N, Barclay, W, McAdoo, SP, Kelleher, P, Willicombe, M (B3) 2021; 397
Ruddy, JA, Connolly, CM, Boyarsky, BJ, Werbel, WA, Christopher-Stine, L, Garonzik-Wang, J, Segev, DL, Paik, JJ (B31) 2021; 80
Bergwerk, M, Gonen, T, Lustig, Y, Amit, S, Lipsitch, M, Cohen, C, Mandelboim, M, Gal Levin, E, Rubin, C, Indenbaum, V, Tal, I, Zavitan, M, Zuckerman, N, Bar-Chaim, A, Kreiss, Y, Regev-Yochay, G (B32) 2021; 385
References_xml – ident: e_1_3_2_30_2
  doi: 10.1101/2021.06.21.21258528
– ident: e_1_3_2_27_2
  doi: 10.3390/diagnostics11040593
– ident: e_1_3_2_21_2
  doi: 10.1093/clinchem/hvaa262
– ident: e_1_3_2_9_2
  doi: 10.1016/bs.aivir.2019.08.002
– ident: e_1_3_2_33_2
  doi: 10.1056/NEJMoa2109072
– ident: e_1_3_2_37_2
  doi: 10.1101/2021.08.19.21262111
– ident: e_1_3_2_17_2
  doi: 10.1093/clinchem/hvaa336
– ident: e_1_3_2_23_2
  doi: 10.1515/cclm-2021-0023
– ident: e_1_3_2_43_2
  doi: 10.1016/S1473-3099(20)30634-4
– volume: 15
  start-page: 93
  year: 2019
  ident: e_1_3_2_25_2
  article-title: Management approaches to hepatitis B virus vaccination nonresponse
  publication-title: Gastroenterol Hepatol (NY)
– ident: e_1_3_2_38_2
  doi: 10.1016/S0140-6736(21)01642-1
– ident: e_1_3_2_4_2
  doi: 10.1016/S0140-6736(21)00502-X
– ident: e_1_3_2_18_2
  doi: 10.1128/JCM.01224-20
– ident: e_1_3_2_22_2
  doi: 10.1093/clinchem/hvaa211
– ident: e_1_3_2_39_2
  doi: 10.1002/jmv.26854
– ident: e_1_3_2_3_2
  doi: 10.1056/NEJMe2028079
– ident: e_1_3_2_40_2
  doi: 10.1021/acsnano.5b02379
– ident: e_1_3_2_6_2
  doi: 10.1038/s41586-020-2852-1
– ident: e_1_3_2_31_2
  doi: 10.1038/s41591-021-01377-8
– ident: e_1_3_2_42_2
  doi: 10.1039/c6cp08749c
– ident: e_1_3_2_16_2
  doi: 10.1101/2020.07.17.20140533
– ident: e_1_3_2_34_2
  doi: 10.1016/S0262-4079(21)00808-3
– ident: e_1_3_2_24_2
  doi: 10.1128/JVI.01828-20
– ident: e_1_3_2_8_2
  doi: 10.12659/MSM.924700
– ident: e_1_3_2_15_2
  doi: 10.1101/2020.09.23.20199604
– ident: e_1_3_2_7_2
  doi: 10.1016/j.vaccine.2020.11.054
– ident: e_1_3_2_35_2
  doi: 10.21873/invivo.12138
– ident: e_1_3_2_26_2
  doi: 10.1128/Spectrum.00247-21
– ident: e_1_3_2_11_2
  doi: 10.1101/2021.02.24.21252368
– ident: e_1_3_2_14_2
  doi: 10.1016/S0140-6736(20)31604-4
– ident: e_1_3_2_5_2
  doi: 10.1016/j.cell.2020.02.058
– ident: e_1_3_2_10_2
  doi: 10.1126/science.abd7728
– ident: e_1_3_2_12_2
  doi: 10.1056/NEJMoa2022483
– ident: e_1_3_2_36_2
  doi: 10.1093/ofid/ofab043
– ident: e_1_3_2_41_2
  doi: 10.1038/srep16145
– ident: e_1_3_2_19_2
  doi: 10.1016/j.ebiom.2020.103101
– ident: e_1_3_2_29_2
  doi: 10.1016/S0140-6736(21)00527-4
– ident: e_1_3_2_20_2
  doi: 10.1128/JCM.02257-20
– ident: e_1_3_2_13_2
  doi: 10.1056/NEJMoa2028436
– ident: e_1_3_2_2_2
  doi: 10.1126/science.abc1227
– ident: e_1_3_2_28_2
  doi: 10.1101/2021.04.27.21256205
– ident: e_1_3_2_32_2
  doi: 10.1136/annrheumdis-2021-220656
– volume: 385
  start-page: 1474
  year: 2021
  end-page: 1484
  ident: B32
  article-title: Covid-19 breakthrough infections in vaccinated health care workers
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2109072
– volume: 368
  start-page: 1060
  year: 2020
  end-page: 1061
  ident: B1
  article-title: Serology assays to manage COVID-19
  publication-title: Science
  doi: 10.1126/science.abc1227
– year: 2021
  ident: B27
  article-title: Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status
  publication-title: medRxiv
  doi: 10.1101/2021.04.27.21256205
– volume: 15
  start-page: 93
  year: 2019
  end-page: 99
  ident: B24
  article-title: Management approaches to hepatitis B virus vaccination nonresponse
  publication-title: Gastroenterol Hepatol (NY)
– volume: 397
  start-page: 1347
  year: 2021
  end-page: 1348
  ident: B28
  article-title: WHO International Standard for anti-SARS-CoV-2 immunoglobulin
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(21)00527-4
– volume: 383
  start-page: 2427
  year: 2020
  end-page: 2438
  ident: B12
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2028436
– volume: 67
  start-page: 404
  year: 2021
  end-page: 414
  ident: B20
  article-title: Commercial serology assays predict neutralization activity against SARS-CoV-2
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa262
– volume: 105
  start-page: 93
  year: 2019
  end-page: 116
  ident: B8
  article-title: Structural insights into coronavirus entry
  publication-title: Adv Virus Res
  doi: 10.1016/bs.aivir.2019.08.002
– volume: 19
  start-page: 8802
  year: 2017
  end-page: 8814
  ident: B41
  article-title: Characterization of fine particles using optomagnetic measurements
  publication-title: Phys Chem Chem Phys
  doi: 10.1039/c6cp08749c
– volume: 9
  year: 2021
  ident: B25
  article-title: Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
  publication-title: Microbiol Spectr
  doi: 10.1128/Spectrum.00247-21
– volume: 80
  start-page: 1351
  year: 2021
  end-page: 1352
  ident: B31
  article-title: High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-220656
– volume: 11
  start-page: 593
  year: 2021
  ident: B26
  article-title: Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test
  publication-title: Diagnostics (Basel, Switzerland)
  doi: 10.3390/diagnostics11040593
– volume: 8
  start-page: ofab043
  year: 2021
  ident: B35
  article-title: Comparative analysis of capillary vs venous blood for serologic detection of SARS-CoV-2 antibodies by RPOC lateral flow tests
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofab043
– year: 2021
  ident: B29
  article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
  publication-title: medRxiv
  doi: 10.1101/2021.06.21.21258528
– year: 2020
  ident: B15
  article-title: Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine
  publication-title: medRxiv
  doi: 10.1101/2020.07.17.20140533
– volume: 396
  start-page: 467
  year: 2020
  end-page: 478
  ident: B13
  article-title: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(20)31604-4
– volume: 27
  start-page: 1205
  year: 2021
  end-page: 1211
  ident: B30
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01377-8
– volume: 66
  start-page: 1538
  year: 2020
  end-page: 1547
  ident: B21
  article-title: Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa211
– year: 2020
  ident: B14
  article-title: Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
  publication-title: medRxiv
  doi: 10.1101/2020.09.23.20199604
– volume: 383
  start-page: 1782
  year: 2020
  end-page: 1784
  ident: B2
  article-title: The power of antibody-based surveillance
  publication-title: N Engl J Med
  doi: 10.1056/NEJMe2028079
– volume: 59
  start-page: 1463
  year: 2021
  end-page: 1467
  ident: B22
  article-title: Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2021-0023
– volume: 62
  start-page: 103101
  year: 2020
  ident: B18
  article-title: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.103101
– volume: 383
  start-page: 1920
  year: 2020
  end-page: 1931
  ident: B11
  article-title: An mRNA vaccine against SARS-CoV-2 - preliminary report
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2022483
– volume: 9
  start-page: 7374
  year: 2015
  end-page: 7382
  ident: B39
  article-title: Scalable DNA-based magnetic nanoparticle agglutination assay for bacterial detection in patient samples
  publication-title: ACS Nano
  doi: 10.1021/acsnano.5b02379
– volume: 181
  start-page: 281
  year: 2020
  end-page: 292.e6
  ident: B4
  article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
– volume: 588
  start-page: 682
  year: 2020
  end-page: 687
  ident: B5
  article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 5
  start-page: 16145
  year: 2015
  ident: B40
  article-title: Quantification of NS1 dengue biomarker in serum via optomagnetic nanocluster detection
  publication-title: Sci Rep
  doi: 10.1038/srep16145
– volume: 20
  start-page: 1390
  year: 2020
  end-page: 1400
  ident: B42
  article-title: Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
  publication-title: Lancet Infectious Diseases
  doi: 10.1016/S1473-3099(20)30634-4
– volume: 58
  year: 2020
  ident: B17
  article-title: Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01224-20
– volume: 398
  start-page: 385
  year: 2021
  end-page: 387
  ident: B37
  article-title: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01642-1
– year: 2021
  ident: B36
  article-title: Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
  publication-title: medRxiv
  doi: 10.1101/2021.08.19.21262111
– volume: 39
  start-page: 197
  year: 2021
  end-page: 201
  ident: B6
  article-title: New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.11.054
– volume: 397
  start-page: P1178
  year: 2021
  end-page: 1181
  ident: B3
  article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(21)00502-X
– volume: 67
  start-page: 742
  year: 2021
  end-page: 752
  ident: B16
  article-title: Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity, and association with virus neutralization test
  publication-title: Clin Chem
  doi: 10.1093/clinchem/hvaa336
– volume: 59
  year: 2021
  ident: B19
  article-title: Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.02257-20
– volume: 26
  year: 2020
  ident: B7
  article-title: An evidence based perspective on mRNA-SARS-CoV-2 vaccine development
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.924700
– volume: 250
  start-page: 8
  year: 2021
  end-page: 9
  ident: B33
  article-title: Are booster shots coming?
  publication-title: New Sci
  doi: 10.1016/S0262-4079(21)00808-3
– volume: 93
  start-page: 3084
  year: 2021
  end-page: 3091
  ident: B38
  article-title: Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19
  publication-title: J Med Virol
  doi: 10.1002/jmv.26854
– volume: 95
  year: 2021
  ident: B23
  article-title: Changes in SARS-CoV-2 spike versus nucleoprotein antibody responses impact the estimates of infections in population- based seroprevalence studies
  publication-title: J Virol
  doi: 10.1128/JVI.01828-20
– year: 2021
  ident: B10
  article-title: Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals
  publication-title: medRxiv
  doi: 10.1101/2021.02.24.21252368
– volume: 34
  start-page: 3039
  year: 2020
  end-page: 3045
  ident: B34
  article-title: Preliminary data of a quantitative point of care test for SARS-CoV-2 antibodies from Greece
  publication-title: In Vivo
  doi: 10.21873/invivo.12138
– volume: 370
  start-page: 1227
  year: 2020
  end-page: 1230
  ident: B9
  article-title: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
  publication-title: Science
  doi: 10.1126/science.abd7728
SSID ssj0001105252
Score 2.2921422
Snippet Serological testing is an important diagnostic support tool in the fight against COVID-19. So far, serological testing has been performed on either lateral...
Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses after...
ABSTRACT Point-of-care (POC) quantification of antibody responses against SARS-CoV-2 spike protein can enable decentralized monitoring of immune responses...
SourceID doaj
pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0039622
SubjectTerms Antibodies, Viral
COVID-19 - diagnosis
COVID-19 Vaccines
Humans
Immunoassay - methods
Immunoglobulin G
immunomagnetic agglutination assay
Pandemics
point-of-care
Point-of-Care Testing
rapid IgG-IgM-IgA combined test
Research Article
S protein trimer
SARS-CoV-2
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus
Vaccination
Vaccines
Title Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring
URI https://www.ncbi.nlm.nih.gov/pubmed/35357223
https://journals.asm.org/doi/10.1128/spectrum.00396-22
https://www.proquest.com/docview/2645859116
https://pubmed.ncbi.nlm.nih.gov/PMC9045215
https://doaj.org/article/422e9e56338048e981a1cd0ba87f39ef
Volume 10
WOSCitedRecordID wos000835142100047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2165-0497
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001105252
  issn: 2165-0497
  databaseCode: DOA
  dateStart: 20210101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2165-0497
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001105252
  issn: 2165-0497
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBbt0kIvpe86bYMKhUJBjS3Zkn1M86CFNklLGvYm9KSGxhuyu4Fc8tszI3uX3RDSSy8-yJIlxjPSN5LmG0I-SJ5b76xiURSOlVZ6Zo2PDNYeWQlYcLlPgcLf1cFBPR43RyupvvBOWE8P3Atuq-Q8NKGS4EqBsoWmLkzhfG5NraJoQsTZF1DPijOVdlcKzM_Gh2NMmIO3UuDi-fz0M0ajSobJckdmesrX1qNE238b1rx5ZXJlDdp_Qh4P4JFu94N-Su6F7hl52KeTvHxO7C9z1nr6c266FDoGExk9mrTdjB1GhoFGdLe_WAfN6TF0TAGxUkzXS3cOT77tgujoiXGu7XcI6TZ8xk78Je0NH3cAX5Df-3vHO1_ZkEOBmSovZyxG71xVGyesFEo4hDe2KUVQsvSNR_ciz6FKLmsFpmkaRDgRUFPIVSzLKF6SUTfpwmtCuTHGCs9DXZnSKGmRKj400ThVQKHJyEcUqB6MYKqTf8FrvRC9TqLXnGckX8hcu4GKHDNi_L2ryadlk7Oeh-Ouyl_wRy4rIoV2KgDF0oNi6X8pVkbeL9RAg8nhOYrpwmQ-1YAhK6T9K2RGXvVqsexKgIIrgFwZUWsKszaW9Tdd-yfRejfIbl9UG_9j8G_II45xGnnJuHpLRiCe8I48cBezdnq-Se6rcb2ZLAaeP672rgFj6hwz
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rapid+Quantitative+Point-Of-Care+Diagnostic+Test+for+Post+COVID-19+Vaccination+Antibody+Monitoring&rft.jtitle=Microbiology+spectrum&rft.au=Moeller%2C+Maria+E&rft.au=Engsig%2C+Frederik+N&rft.au=Bade%2C+Melanie&rft.au=Fock%2C+Jeppe&rft.date=2022-04-27&rft.pub=American+Society+for+Microbiology&rft.eissn=2165-0497&rft.volume=10&rft.issue=2&rft_id=info:doi/10.1128%2Fspectrum.00396-22&rft.externalDocID=00396-22
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon